Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease
Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: high dose chemotherapy and autologous hematopoietic cell transplant
Eligibility
Inclusion Criteria:- active chronic GvHD
- ANC > 1000/mm^3
- therapeutic cyclosporine Exclusion Criteria:- uncontrolled systemic infection
- elevated serum creatinine
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.